# A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

> **NCT02413008** · PHASE2 · COMPLETED · sponsor: **ITF Research Pharma, S.L.U.** · enrollment: 61 (actual)

## Conditions studied

- Vaginal Atrophy

## Interventions

- **DRUG:** estriol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02413008
- **Lead sponsor:** ITF Research Pharma, S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-16
- **Primary completion:** 2017-02-10
- **Final completion:** 2017-02-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413008, "A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02413008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*